Enterome to Present Data on EO2401 in Adrenal Tumors at the European Society for Medical Oncology (ESMO) 2023 Congress

Oral Presentation at ESMO will feature updated results from Phase 1/2 SPENCER studyPARIS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that updated data from its Phase 1/2 SPENCER study on EO2401, in combination with nivolumab in patients with adrenal tumors, will be presented in an oral session at the European

Related Keywords

Madrid ,Spain ,France ,Paris ,France General ,Guillaume Bayre ,Weid Europe ,Gustave Roussy Villejuif ,Eric Baudin ,Ashleyr Robinson ,Lifesci Advisors ,European Society For Medical Oncology ,Health Science ,Head Of External Communications ,Oral Presentation ,European Society ,Medical Oncology ,Associate Professor ,Endocrine Oncology Unit ,Gustave Roussy ,Paper Session ,Tumor Associated Antigens ,Universal Cancer Peptide ,Adrenal Tumors ,Immunomodulatory Drugs ,Inflammatory Diseases ,Phase 2 Clinical Trial ,Europe ,Endocrine Oncology ,Osmo ,